U.S. FDA Vaccine Committee Schedules Digital Meeting For 1/26/23
The U.S. Food and Drug Administration (FDA) has scheduled a Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting for January 26, 2023.
FDA confirmed it intends to make background material available to the public no later than two business days before the meeting. In addition, materials for this meeting will be available on the VRBPAC main webpage.
Furthermore, interested persons may present data, information, or views, orally or in writing, on issues pending before the Committee using this docket number: FDA-2022-N-2810.
Comments received on or before January 18, 2023, will be provided to the VRBPAC. Comments received after January 18, 2023, and by January 25, 2023, will be considered by the FDA.
Additional meeting information is available on this FDA webpage.
The VRBPAC reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products intended to prevent, treat, or diagnose human diseases.
And, as required, any other products for which the FDA has regulatory responsibility.
The Committee also considers the quality and relevance of the FDA's research program, which provides scientific support for regulating these products and makes appropriate recommendations to the Commissioner of the FDA.